Skip to Content

RTOG 1016 - A PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VERSUS CHEMORADIOTHERAPY IN HPV-ASSOCIATED OROPHARYNX CANCER

Objective
The purpose of this study is to compare the effects, good and/or bad, of two standard treatments for head and neck cancer: radiation therapy and cisplatin or radiation therapy and cetuximab.
IRB Protocol Number
12-0414
Principal Investigator(s)
DAVID RABEN

Cancer Trials

  • Head and Neck Cancers
Sponsor(s)
RTOG
Contact
ROBYN SWING at 720-848-0607
or ROBYN.SWING@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. Group 1 patients will receive radiation therapy for about 6 weeks and study drug A on days 1 and 22 during radiation. Group 2 patients will receive a dose of study drug B a week before radiation. If the tolerate study drug B well, they will receive study drug B once a week for 6 weeks during radiation therapy, and once after radiation therapy. A follow up period will consist of clinic visits after one and three months of treatment, every three months two years after treatment, every six months three years after treatment, and once a year for the rest of their lifetimes. // Eligibility criteria include but are not limited to 18 years or older, with HPV-associated oropharynx cancer.